Location of Repository

Subgroup Economic Analysis for Glioblastoma in a Health Resource-Limited Setting

By Bin Wu, Yifeng Miao, Yongrui Bai, Min Ye, Yuejuan Xu, Huafeng Chen, Jinfang Shen and Yongming Qiu
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3325281
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2008). Malignant gliomas in adults.
    2. (2010). Glioblastoma therapy: going beyond Hercules Columns.
    3. (2008). Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.
    4. (2002). Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.
    5. (2008). Mechanisms of disease: temozolomide and glioblastoma–look to the future.
    6. (2005). Drug Insight: temozolomide as a treatment for malignant glioma–impact of a recent trial.
    7. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    8. (2011). Evolving strategies: future treatment of glioblastoma.
    9. (2010). Standard Therapy for Glioblastoma-A Review of Where We Are.
    10. (2008). Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
    11. (2006). PCV chemotherapy for recurrent glioblastoma.
    12. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
    13. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma.
    14. (2006). Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
    15. (2006). Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group.
    16. (1999). [Study of formula for calculating body surface areas of the Chinese adults].
    17. (2007). The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess 11: iii–iv,
    18. (2004). Use of costeffectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?
    19. (2007). The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health technology assessment 11: iii–iv,
    20. (2008). Costeffectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the
    21. (2005). Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
    22. (2009). Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Expert review of pharmacoeconomics & outcomes research 9:
    23. (2010). Bevacizumab: in previously treated glioblastoma.
    24. (2010). Salvage therapy with single agent bevacizumab for recurrent glioblastoma.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.